Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation.

MLA

Ip, Winnie, et al. “Multicenter Phase 1/2 Application of Adenovirus-Specific T Cells in High-Risk Pediatric Patients after Allogeneic Stem Cell Transplantation.” Cytotherapy, vol. 20, no. 6, June 2018, pp. 830–38. EBSCOhost, https://doi.org/10.1016/j.jcyt.2018.03.040.

APA

Ip, W., Silva, J. M. F., Gaspar, H., Mitra, A., Patel, S., Rao, K., Chiesa, R., Amrolia, P., Gilmour, K., Ahsan, G., Slatter, M., Gennery, A. R., Wynn, R. F., Veys, P., & Qasim, W. (2018). Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation. Cytotherapy, 20(6), 830–838. https://doi.org/10.1016/j.jcyt.2018.03.040

Chicago

Ip, Winnie, Juliana M F Silva, Hubert Gaspar, Arindam Mitra, Shreenal Patel, Kanchan Rao, Robert Chiesa, et al. 2018. “Multicenter Phase 1/2 Application of Adenovirus-Specific T Cells in High-Risk Pediatric Patients after Allogeneic Stem Cell Transplantation.” Cytotherapy 20 (6): 830–38. doi:10.1016/j.jcyt.2018.03.040.